France Relaxes Stance On Biosimilar Switching
This article was originally published in SRA
Executive Summary
The French regulatory agency ANSM has relaxed its stance on biosimilar interchangeability to state that while in principle patients should preferably not be switched between a reference drug and a biosimilar during their course of treatment, this can be done provided the patient agrees and their treatment is closely monitored1.
You may also be interested in...
French Govt Calls For 70% Biosimilar Prescribing Rate; Substitution Groups Published
Moves are under way in France to give the biosimilars market a shot in the arm by setting a 70% target for initial prescribing rates and encouraging pharmacist substitution through the creation of similar biological medicine groups.
French Govt Calls For 70% Biosimilar Prescribing Rate; Substitution Groups Published
Moves are under way in France to give the biosimilars market a shot in the arm by setting a 70% target for initial prescribing rates and encouraging pharmacist substitution through the creation of similar biological medicine groups.
France 2017: More Price Cuts, Rebates, Generics and Biosimilars, And A New Innovation Fund
The French pharmaceutical industry has reacted angrily to some of the provisions in the 2017 social security financing bill, arguing that the measures are inappropriate and that the government is taking a purely financial approach to addressing the costs of healthcare products, rather than taking wider public health considerations into account.